Cancer-related Fatigue
December 7, 2023
Fatigue is one of the most common symptoms experienced by those living with CLL and SLL, and it is also commonly overlooked,underreported, and undertreated.
Fatigue is one of the most common symptoms experienced by those living with CLL and SLL, and it is also commonly overlooked,underreported, and undertreated.
Chronic lymphocytic leukemia (CLL) is a slow-growing blood cancer involving the abnormal overgrowth of
a type of white blood cell called B-lymphocytes.
Autoimmune hemolytic anemia (AIHA) is the most common autoimmune condition associated with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Tumor lysis syndrome is a rare condition that can happen due to the rapid death of cancer cells. When the cancer cells are killed, the debris from inside the cells enters the bloodstream.
Education On-Demand Education On-Demand The varied educational activities offered by CLL Society are your opportunities to learn basic information, dive deep into specific topics, or stay abreast of cutting-edge news and
There are multiple excellent choices between limited-duration and continuous targeted therapies that all can offer durable disease control.
Though it is still early, the combination of pirtobrutinib-venetoclax-obinutuzumab appears to have good efficacy in patients with Richter transformation.
August 2025 marks two full years that I’ve enjoyed the benefits from my trial of epcoritamab, a bispecific T-cell-engaging monoclonal antibody for my CLL. But the last remains of my chronic lymphocytic leukemia (CLL) have remained stubbornly persistent for about a year and a half.
An ongoing phase 2 clinical trial is testing whether adding venetoclax to first-line BTK inhibitor therapy can deepen remissions for CLL patients.